CTAG1B and melanoma: The frequency of anti-NY-ESO-1 antibody responses in patients with advanced NY-ESO-1-expressing tumors (including melanoma, lung cancer, bladder cancer, ovarian cancer, and breast cancer) is in the range of 25–50% [27-28].